Revival of Dormant Antipsychotic Class: LB Pharma’s Phase II Success with LB-102
LB Pharma's Phase II Success:
LB Pharmaceuticals has announced positive topline results from the NOVA 1 Phase 2 trial of LB-102, a potential first-in-class benzamide antipsychotic for the treatment of schizophrenia in the U.S.24.
Efficacy and Safety:
The trial demonstrated statistically significant reductions in PANSS total scores at all dose levels compared to placebo, with clinically meaningful effect sizes observed across all doses. LB-102 was generally safe and well-tolerated, with a low incidence of extrapyramidal symptoms (EPS) and minimal QT interval prolongation2.
Revival of Dormant Class:
The success of LB-102 revives a dormant class of antipsychotics, offering a new treatment option for patients with acute schizophrenia. This development is significant given the lack of major advancements in schizophrenia treatment over the past 70 years24.
Comparison to Existing Treatments:
Unlike many existing antipsychotics, LB-102 showed a favorable safety profile with minimal side effects such as weight gain and sedation, which are common issues with current treatments2.
Future Development:
Based on these findings, LB Pharmaceuticals plans to advance LB-102 into Phase 3 clinical development and explore its potential in additional psychiatric indications, including a long-acting injectable formulation2.
Sources:
2. https://www.globenewswire.com/news-release/2025/01/08/3006104/0/en/LB-Pharmaceuticals-Announces-Positive-Topline-Results-from-Phase-2-Trial-of-LB-102-in-Schizophrenia.html